Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots (WBA) reports better-than-expected Q3 earnings, with robust sales contributions from the International and Walgreens Health segments.

Walgreens Boots (WBA) Q3 Earnings Top Estimates, Revenues Miss

AT&T

TC Energy

Walgreens, TC Energy, and AT&T have all been making regular dividend payments for a long time.

Want to Make $400 a Month in Dividends? Invest in These 3 Stocks

What pandemic? With COVID-19 vaccinations and urgent care visits dropping through spring as infection fears faded, Big Pharmacy is looking to get back on track with expansion plans, a recovery in prescriptions and wellness sales products, and more access to primary care via the growing networks of retail primary care clinics being pursued by major […]

Walgreens Looks to Primary Care and Virtual for Growth, as Do Rivals

Walgreens Boots Alliance, Inc. (NASDAQ:WBA ) Q3 2022 Earnings Conference Call June 30, 2022 8:30 AM ET Company Participants Tiffany Kanaga - Vice President, Global Investor Relations Rosalind Brewer - Chief Executive Officer James Kehoe - Executive Vice President and Global Chief Financial Officer John Standley - President, Walgreens Conference Call Participants Lisa Gill - JPMorgan George Hill - Deutsche Bank Michael Cherny - Bank of America Elizabeth Anderson - Evercore ISI Steven Valiquette - Barclays Operator Good morning. My name is Chris, and I'll be your conference operator today.

Walgreens Boots Alliance, Inc. (WBA) CEO Rosalind Brewer on Q3 2022 Results - Earnings Call Transcript

Walgreens Boots Alliance (NASDAQ: WBA) is one of our top picks for long-term oriented high-yield investors because of the turnaround story. The company has been working to realign itself for growth over the past few years and those efforts are working.

The Value Of High-Yielding Walgreens Boots Alliance Deepens

Walgreens Boots Alliance Inc (NASDAQ: WBA) on Thursday said lower demand for COVID vaccine and tests resulted in a significant year-on-year hit to its third-quarter results. Shares are down more than 3.0% this morning.

Walgreens stock down despite market-beating Q3 results

Walgreens (WBA) stock is falling on Thursday following the release of the company's earnings report for its fiscal third quarter of 2022. The post Walgreens (WBA) Stock Slides Following Q3 Earnings Report appeared first on InvestorPlace.

Walgreens (WBA) Stock Slides Following Q3 Earnings Report

Walgreens wants to double the number of prescriptions being filled by its robot-powered micro fulfillment centers, the pharmacy chain's chief executive said Thursday (June 30). Speaking on a conference call to announce third quarter 2022 earnings results, Walgreens Boots Alliance CEO Rosalind Brewer said those centers, first launched earlier this year, now fill about 20% […]

Walgreens Plans to Double Robot Pharmacy Use

Walgreens (WBA) delivered earnings and revenue surprises of 1.05% and 0.43%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots Alliance (WBA) Beats Q3 Earnings Estimates

Walgreens Boots Alliance Inc's (NASDAQ: WBA) Q3 FY22 sales decreased 4.2% Y/Y to $32.6 billion, down 2.8% on a constant currency basis, beating the consensus of $32.06 billion. Adjusted EPS reached $0.96, beating the consensus of $0.92, down 28.9% on a constant currency basis against.

Walgreens Posts Fall In Q3 Profit On Opioid Settlement, Lower Pharmacy Sales

Walgreens reported quarterly profits well below the year-ago period thanks largely to costs to settle with the state of Florida claims its pharmacies contributed to the opioid epidemic.

Opioid Settlement Drags Walgreens Profits

Drugstore chain Walgreens Boots Alliance Inc posted a 76% fall in quarterly profit on Thursday, hurt by its opioid settlement with Florida and a decrease in U.S. pharmacy sales on waning demand for COVID-19 vaccinations.

Walgreens profit plunges on opioid settlement, lower pharmacy sales

Walgreens Boots Alliance Inc. WBA, -0.22% reported fiscal third-quarter net income totaling $289 million, or 33 cents per share, down from $1.197 billion, or $1.38 per share, last year. Adjusted EPS of 96 cents beat the FactSet consensus for 92 cents.

Walgreens beats Street views but sees sharp profit decline

Drugstore chain Walgreens reports adjusted earnings of 96 cents a share, beating estimates for 90 cents.

Walgreens Earnings Beat Expectations but Fall Sharply From Year Earlier

Walgreens Boots Alliance's quarterly earnings beat Wall Street expectations as the chain saw online sales jump in the U.S. and retail sales bounce back in the fiscal third quarter.

Walgreens reports quarterly sales, profit above Wall Street expectations

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the third quarter of fiscal 2022, which ended May 31, 2022.

Walgreens Boots Alliance Reports Fiscal 2022 Third Quarter Results

Some of the stocks that may grab investor focus today are: Wall Street expects Walgreens Boots Alliance, Inc. (NASDAQ: WBA) to report quarterly earnings at $0.92 per share on revenue of $32.06 billion before the opening bell. Walgreens shares fell 0.1% to $40.86 in after-hours trading.

RH, Walgreens And 3 Stocks To Watch Heading Into Thursday

Albemarle

Franklin Resources

Caterpillar

Clorox

Ecolab

Lowe's

Medtronic

ProShares S&P 500 Dividend Aristocrats ETF

Nucor

Sherwin-Williams

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

NOBL gains 0.31% in May but is down 5.99% in 2022 after the first 5 months. Thus far, through June 28th, the dividend aristocrat ETF is down 6.22%, inclusive of its dividend payment this month.

My Best Dividend Aristocrats For July 2022

It's proved tough to sell one of the staples of Britain's beleaguered High Street, tough as old Boots. Public ‘buyers' are now reportedly sought, practically as buyers of last resort, after private equity takeover talks broke down, with an IPO potentially eyed to bring back the soap-n-smellies retailer to the stock market.

An unwanted child, Walgreens' next moves will be key for the future of Boots

Boots owner Walgreens hinted it might try to re-float the chemist chain after attempts to sell the business fell through. In a statement last night, Walgreens (WBA) confirmed that it would retain ownership of Boots after ending an auction process that had lasted for several months.

Boots to stay with Walgreens as sale plans falls through

The company should also see continued benefits from its international pharmaceuticals business and the expansion of its healthcare platform - Walgreens Health - a trend seen over the recent quarters.

What To Expect From Walgreens Stock As It Reports Its Q3 Results?

After a six-month review period that saw its own stock and the broader markets falling by more than 20%, Walgreens announced Tuesday (June 28) that it has decided to retain ownership of its U.K.-based Boots unit, as well as its No7 cosmetics brand. In a deal that had been reputed to be worth up to $7.5 […]

Walgreens Won't Sell Boots, Cites Dramatic Shift in Financial Markets

Field Trip Health Ltd

Constellation Brands

The three major U.S. equity indexes closed lower Monday, with the Nasdaq dipping by 0.72%, the S&P 500 sliding 0.3% and the Dow Jones industrials closing down 0.2%.

Earnings Previews: Constellation Brands, Field Trip Health, NovaGold, Walgreens

Walgreens Boots Alliance Inc  (NASDAQ:WBA) is ditching plans to sell its pharmacy business in the United Kingdom, noting no third parties made suitable offers on its Boots chain, which is made up of 2,200 stores including pharmacies, health, and beauty stores.

Walgreens Boots Alliance Ditches U.K. Business Sale

The Walgreens Boots Alliance (WBA) announced its decision to keep its Boots and No7 Beauty Company businesses under its existing ownership this morning, U.S. time.

News for Walgreens Stock (WBA)